Thursday, June 22, 2023
8 am PT, 11 am ET, 17:00 CET
Rigorous specificity analysis is critical for successful drug development and a safety requirement for antibody-based therapies, such as CAR-T, entering IND. Tissue cross-reactivity (TCR) studies have been traditionally used to screen for off-target binding; however, their predictive value for in vivo safety and toxicity is poor. Integral Molecular has developed the Membrane Proteome Array (MPA) platform to de-risk antibody-based therapeutics by testing specificity across the full human membrane proteome expressed in live cells. Using sensitive high-throughput flow cytometry to identify binding interactions on a protein level, this technology has emerged as the leading solution for antibody specificity profiling.
In this GEN webinar, our panelists will discuss their experiences using the MPA to rapidly identify potential off-target interactions, resulting in successful IND filings for CAR-T cell therapies where conventional approaches did not suffice. We will also describe the newest additions to this 6,000-protein cell array and the status of its consideration by the FDA as a qualified Drug Development Tool.
With a focus on specificity screening, this webinar assembles experts in antibody discovery and development and features presentations from Integral Molecular, Cabaletta Bio, and The University of Pennsylvania.
- Understand how Integral Molecular’s MPA is used to identify potential off-target binding liabilities
- Learn how MPA data supports IND submissions with advantages over traditional tissue cross-reactivity studies
- Discover how the MPA was used to rapidly evaluate the specificity of novel CAR-T cell therapies for autoimmunity and cancer